Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection.
about
A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccineHerpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccineProduction of immunogenic West Nile virus-like particles using a herpes simplex virus 1 recombinant vectorA herpesvirus encoded deubiquitinase is a novel neuroinvasive determinantConstruction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein.Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus.Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2.Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpes simplex virus type 1 vaccine strain.Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells.Prospects for control of herpes simplex virus disease through immunization.Recent progress in herpes simplex virus immunobiology and vaccine researchActive immunization in the United States: developments over the past decade.Rationalizing the development of live attenuated virus vaccinesHerpes simplex viruses: is a vaccine tenable?The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice.High-purity preparation of HSV-2 vaccine candidate ACAM529 is immunogenic and efficacious in vivoHerpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity.Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital modelMechanism of reduced T-cell effector functions and class-switched antibody responses to herpes simplex virus type 2 in the absence of B7 costimulationDirected antigen delivery as a vaccine strategy for an intracellular bacterial pathogen.Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 diseaseEvidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa.Evaluation of infectious titer in a candidate HSV type 2 vaccine by a quantitative molecular approach.Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigsFuture of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex VaccineImmunization with a replication-defective herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents ocular disease.Glycoprotein D adjuvant herpes simplex virus vaccine.A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.Disruption of the U(L)41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes.The challenge of developing a herpes simplex virus 2 vaccine.Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs.Towards an effective genital herpes vaccine: past lessons and future prospects.Serological diagnosis of human herpes simplex virus type 1 and 2 infections by luciferase immunoprecipitation system assay.Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection.Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigsComparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines?Maternal Antiviral Immunoglobulin Accumulates in Neural Tissue of Neonates To Prevent HSV Neurological Disease.Effective vaccination against long-term gammaherpesvirus latency.
P2860
Q21089976-3AC77050-9618-4D96-A2E2-95E3CAD81843Q21562177-A6BA3424-C533-45BD-9B3F-917642D58E18Q26247032-7464F60D-2E17-41E6-81CF-429F610C8884Q33432679-8935E754-C28D-4593-BE74-FFE11F4C9036Q33724497-3B7B8691-E753-4FC7-933B-1BF65AF8CB21Q33810277-F9052D18-CD66-4200-86BD-7D78DE166D5EQ33810615-11B4EDDF-7510-4C1D-826F-76A2D98F84D2Q33826884-357CE608-5F71-4504-9087-09B8F4052A28Q33836053-47FA68C3-21A9-44CD-BE2B-63871B4FA193Q33866424-0BA15C2B-848B-4187-A6B4-9D2A9A8F2BF0Q33963713-979AADAE-5F8E-40BF-8B42-203E981772DAQ33975799-704318E4-E128-4200-A528-E293FB166B90Q34119676-8949C635-7B74-40FD-AF96-407FAA0600F1Q34139375-023A0E37-5BBD-4D03-9D84-EACCC24480C9Q34150713-A9231E0E-6856-49A4-9636-A75E4A9FDC0DQ34331569-E1C1D4DC-41B9-4D24-AD89-FE97174D8A9DQ34335296-BEAC7025-0A8D-48A8-AB79-3754CBB51D6BQ34447379-2AB92F8F-70FD-4E69-983B-BBADE8C5167CQ34471729-4FB66E2B-0EE2-4363-A3F9-40A3B6A4FB9AQ34596940-E61C9B22-6613-4BA1-9A5B-EC768971FF69Q34742583-EF06B0D7-0D1A-4C29-9C72-0384A787A6A9Q34834264-8A8A0C70-179F-4B24-9960-F30F0D278B8BQ35061783-1824D1E6-F9E9-4EAA-A100-C3DCDE7D6828Q35249684-CBC64A8E-9163-4668-9551-1C3B8CD18364Q36025675-F4A3BE6C-A371-48FB-A10B-A1E42D8F6C0AQ36176893-266DB474-5E4F-4595-A40A-2209151B5DAFQ36284536-B5430D4E-EE3F-4479-850B-CC136843A444Q36433844-DAE9FACA-F9CB-4DC9-943B-1EB9C82CD110Q36570266-1AD3DC1B-CC46-4E12-9D5D-3489FE8DF925Q36671106-3988FA23-088D-46F7-B7E1-CFBDC826A20AQ36931089-95E78EED-BAE2-4524-BAF2-563B91E1B1E8Q36991575-3FA5B981-5383-4109-90F2-69D504270FDAQ37116538-6F6D4622-D427-4C7A-A27C-A72BD9645460Q37125722-EE2ED444-D614-44CF-A416-226ABED37480Q37160338-667BDCC6-127B-44B3-B7C5-56A9E8B34A91Q37305719-CA65C4BF-1536-4EC2-8941-49546F378414Q37746861-0CA53797-9DBD-43C4-9308-1BA8779DCB6DQ38212516-6986F04F-1607-4BC5-9EAD-FFA6D0AE84C1Q38692329-087B36B7-B4DA-4234-9CA4-98502B7B9A04Q39700306-30D99E56-ACA6-434C-9F3A-91ACDDA6F323
P2860
Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Immunization against genital h ...... oductive and latent infection.
@ast
Immunization against genital h ...... oductive and latent infection.
@en
type
label
Immunization against genital h ...... oductive and latent infection.
@ast
Immunization against genital h ...... oductive and latent infection.
@en
prefLabel
Immunization against genital h ...... oductive and latent infection.
@ast
Immunization against genital h ...... oductive and latent infection.
@en
P2093
P2860
P356
P1476
Immunization against genital h ...... oductive and latent infection.
@en
P2093
X J Da Costa
P2860
P304
P356
10.1073/PNAS.96.12.6994
P407
P577
1999-06-01T00:00:00Z